Literature DB >> 32057098

Methylation-based algorithms for diagnosis: experience from neuro-oncology.

Jessica C Pickles1,2, Thomas J Stone1,2, Thomas S Jacques1,2.   

Abstract

Brain tumours are the most common tumour-related cause of death in young people. Survivors are at risk of significant disability, at least in part related to the effects of treatment. Therefore, there is a need for a precise diagnosis that stratifies patients for the most suitable treatment, matched to the underlying biology of their tumour. Although traditional histopathology has been accurate in predicting treatment responses in many cases, molecular profiling has revealed a remarkable, previously unappreciated, level of biological complexity in the classification of these tumours. Among different molecular technologies, DNA methylation profiling has had the most pronounced impact on brain tumour classification. Furthermore, using machine learning-based algorithms, DNA methylation profiling is changing diagnostic practice. This can be regarded as an exemplar for how molecular pathology can influence diagnostic practice and illustrates some of the unanticipated benefits and risks.
© 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Keywords:  CNS tumours; DNA methylation profiling; Ewing's tumour; algorithm; astrocytoma; classification; diagnosis; ependymoma; glioblastoma; medulloblastoma; neuroblastoma; pathology

Mesh:

Substances:

Year:  2020        PMID: 32057098     DOI: 10.1002/path.5397

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  7 in total

Review 1.  2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist.

Authors:  Cillian McNamara; Kshitij Mankad; Stefanie Thust; Luke Dixon; Clara Limback-Stanic; Felice D'Arco; Thomas S Jacques; Ulrike Löbel
Journal:  Neuroradiology       Date:  2022-07-22       Impact factor: 2.995

2.  DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.

Authors:  Maritza S Mosella; Thais S Sabedot; Tiago C Silva; Tathiane M Malta; Felipe Segato Dezem; Karam P Asmaro; Michael Wells; Abir Mukherjee; Laila M Poisson; James Snyder; Ana C deCarvalho; Tobias Walbert; Todd Aho; Steven Kalkanis; Paula C Elias; Sonir R Antonini; Jack Rock; Houtan Noushmehr; Margaret Castro; Ana Valeria Castro
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

3.  Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma.

Authors:  Rahul Kumar; Kyle S Smith; Maximilian Deng; Colt Terhune; Giles W Robinson; Brent A Orr; Anthony P Y Liu; Tong Lin; Catherine A Billups; Murali Chintagumpala; Daniel C Bowers; Timothy E Hassall; Jordan R Hansford; Dong Anh Khuong-Quang; John R Crawford; Anne E Bendel; Sridharan Gururangan; Kristin Schroeder; Eric Bouffet; Ute Bartels; Michael J Fisher; Richard Cohn; Sonia Partap; Stewart J Kellie; Geoffrey McCowage; Arnold C Paulino; Stefan Rutkowski; Gudrun Fleischhack; Girish Dhall; Laura J Klesse; Sarah Leary; Javad Nazarian; Marcel Kool; Pieter Wesseling; Marina Ryzhova; Olga Zheludkova; Andrey V Golanov; Roger E McLendon; Roger J Packer; Christopher Dunham; Juliette Hukin; Maryam Fouladi; Claudia C Faria; Jose Pimentel; Andrew W Walter; Nada Jabado; Yoon-Jae Cho; Sebastien Perreault; Sidney E Croul; Michal Zapotocky; Cynthia Hawkins; Uri Tabori; Michael D Taylor; Stefan M Pfister; Paul Klimo; Frederick A Boop; David W Ellison; Thomas E Merchant; Arzu Onar-Thomas; Andrey Korshunov; David T W Jones; Amar Gajjar; Vijay Ramaswamy; Paul A Northcott
Journal:  J Clin Oncol       Date:  2021-01-27       Impact factor: 44.544

4.  Combinations of Single-Gene Biomarkers Can Precisely Stratify 1,028 Adult Gliomas for Prognostication.

Authors:  Aden Ka-Yin Chan; Zhi-Feng Shi; Kay Ka-Wai Li; Wei-Wei Wang; Hong Chen; Nellie Yuk-Fei Chung; Danny Tat-Ming Chan; Wai-Sang Poon; Herbert Ho-Fung Loong; Xian-Zhi Liu; Zhen-Yu Zhang; Ying Mao; Ho-Keung Ng
Journal:  Front Oncol       Date:  2022-04-26       Impact factor: 5.738

5.  DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles.

Authors:  Sepehr Safaei; Malte Mohme; Judith Niesen; Ulrich Schüller; Michael Bockmayr
Journal:  Oncoimmunology       Date:  2021-06-17       Impact factor: 8.110

Review 6.  Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.

Authors:  Sebastian Brandner; Alexandra McAleenan; Hayley E Jones; Ashleigh Kernohan; Tomos Robinson; Lena Schmidt; Sarah Dawson; Claire Kelly; Emmelyn Spencer Leal; Claire L Faulkner; Abigail Palmer; Christopher Wragg; Sarah Jefferies; Luke Vale; Julian P T Higgins; Kathreena M Kurian
Journal:  Neuropathol Appl Neurobiol       Date:  2022-03-03       Impact factor: 6.250

7.  Advanced molecular pathology for rare tumours: A national feasibility study and model for centralised medulloblastoma diagnostics.

Authors:  Stephen Crosier; Debbie Hicks; Edward C Schwalbe; Daniel Williamson; Sarah Leigh Nicholson; Amanda Smith; Janet C Lindsey; Antony Michalski; Barry Pizer; Simon Bailey; Nick Bown; Gavin Cuthbert; Stephen B Wharton; Thomas S Jacques; Abhijit Joshi; Steven C Clifford
Journal:  Neuropathol Appl Neurobiol       Date:  2021-05-02       Impact factor: 8.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.